This Health Company Secures FDA Clearance For Netherton Syndrome Plan

Quoin Pharmaceuticals Secures FDA Clearance for QRX003 Netherton Syndrome Clinical Optimization Plan.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant development for the medical industry and patients suffering from Netherton Syndrome, Quoin Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared their Clin…